Abstraprimary refractory DLBCL including refractory disease and the secondline age-adjusted international prognostic index. In de novo DLBCL cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts for event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplant-eligible patients undergoing ICE second-line chemotherapy (SLT) followed by high dose therapy (HDT) and ASCT to see if were they prognostic in the salvage setting. Pretreatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT eventfree or overall survival based upon the cell of origin or any of the common pathologic markers examined. Conclusion: the cell of origin as determined by IHC does not predict outcome in transplant-eligible patients with relapsed or primary refractory DLBCL.
Introduction
DLBCL is a heterogeneous disorder that can be subdivided into several subgroups by distinctive patterns of gene expression [1] [2] [3] ; clinical outcomes can be divided into two groups by cell of origin: germinal center phenotype (GC) versus non-GC. These results have been translated into a clinically applicable approach For personal use only. on September 14, 2017. by guest www.bloodjournal.org From using immunohistochemistry on tissue microarray (TMA) 4 . Tumors were classified as GC vs non-GC based on three markers, CD10, BCL6, and MUM1 (Table 1) , and the outcome difference was confirmed (5 year overall survival 76% GC v. 34% non-GC) 4 .
Molecular signatures associated with outcome of patients with relapsed and refractory disease have not been reported. Lack of research in this setting stems from the following: non-uniform second-line therapy (SLT); incomplete clinical databases; and lack of biopsy specimens in patients who relapse. Since 1993 we have conducted sequential studies of ICE chemotherapy as SLT for relapsed and primary refractory DLBCL requiring a biopsy prior to SLT [5] [6] [7] [8] [9] . In this analysis we sought to determine if the cell of origin was an important factor in the outcome of patients with relapsed and refractory DLBCL. In addition, we wanted to determine if a number of other commonly reported pathologic markers in de novo DLBCL were prognostic in the second-line setting.
Study Des

PATIENTS
The study group consisted of 150 transplant-eligible patients with relapse/primary refractory DLBCL enrolled on one of 3 IRB approved clinical trials between 3/93 and 4/01; the clinical outcome has already been reported 8 .
All patients received ICE-based SLT; no patient received rituximab. Tissue suitable for construction of a TMA was available on 88 patients and with RNA For personal use only. on September 14, 2017. by guest www.bloodjournal.org From for expression profiling on 17 cases. All pts were on a IRB approved protocol and informed consent was provided according to the Declaration of Helsinki.
METHODS
TMA were constructed from the pre-ICE biopsy specimen as previously published 10 . Consecutive TMA sections were stained with CD10, bcl-6, and MUM1 to determine GC versus non-GC molecular phenotype as well as with bcl-2, p53, MUC-1, MDR, and MIB-1; positive and negative cutoffs were previously reported 11 . Expression profiling was performed using Affymetrix HG-U95A arrays as described previously. 12 Specimens from this cohort were classified as GC vs non-GC using 18 of the 27 genes in the Wright classifier 13 present on the HG-U95A array.
STATISTICS
The hypothesis of this study was that the cell of origin, as defined by immunohistochemistry, of the relapse/refractory biopsy specimen would be predictive of overall survival (OS) and event-free survival (EFS). An event was defined as progression of disease, secondary malignancy, death from toxicity, or death from DLBCL. OS and EFS curves were generated by the Kaplan-Meier method. Given the sample size the probability of missing a hazard ratio > 2.5 is less than 12%. The association of the clinical and pathologic variables on these endpoints was examined using the log-rank test. The cutoff for univariate significance was 0.05. 
Results and Discussion
In the past 10 years our group has conducted prospective intent to treat clinical trials utilizing dose-dense SLT followed by HDT/ASCT for patients with chemosensitive DLBCL 5-9 . In the context of these studies we have : 1) established ICE as a highly active regimen for SLT; 2) shown that a complete response (CR) to ICE improves long term EFS; 3) reported that patients with primary refractory disease that is chemoresponsive to ICE have the same outcome as patients with chemosensitive relapsed disease; 4) identified and validated a simple 3 factor prognostic model (stage, LDH, and performance status) evaluated at the initiation of ICE chemotherapy predicts outcome; and lastly 5) showed that the addition of rituximab to the ICE regimen increases the CR rate pre-HDT.
Unfortunately despite a large database of patients with relapsed and refractory disease the outcome of patients with identical clinical parameters varies significantly. For example, in the most favorable patient, one with relapsed disease, with favorable risk factors, in CR pre-HDT, EFS is only 66%.
We wanted to test the hypothesis that markers of prognosis important in untreated DLBCL such as cell of origin and others would impact outcome in the second-line setting.
The median follow-up of surviving patients is 6.5 years. The actuarial EFS and OS are 29.5% and 39%, respectively; for the transplanted patients it is 39%
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From and 54%. The patient characteristics (Table 1) and outcomes of this subset of 88 patients are similar identical to the entire population of patients with DLBCL (data not shown) 8 .
The median age of the patients was 49 and 72% were male. Forty-eight patients (55%) were prognostically favorable based upon the second-line AAIPI; 40 patients (45%) had primary refractory DLBCL. Sixty-five patients (74%) had chemosensitive disease to ICE SLT. Using the immunohistochemical model, 28 patients had GCB and 60 patients had non-GCB DLBCL. We were able to obtain the original biopsy specimen on 21 of the 88 patients and there was 100% concordance with the relapsed/refractory biopsy specimen concerning cell of origin using the Hans algorithm. There were minor differences which did not effect classification: loss of BCL6 expression in 5 cases; and loss of MUM1 expression in 4 cases.
Expression profiling of 17 available specimens revealed that of the 10 that could be classified with at least 90% probability, 9 (4 GC and 5 non-GC) were in agreement with the classification by the immunohistochemical method. In a panel of 33 patient samples at diagnosis DLBCL, a similar level of concordance was obtained (86%) (data not shown). Pretreatment prognostic factors including the second-line IPI, age-adjusted IPI, relapse vs. primary refractory disease were well balanced between the GC or non-GC cohorts.
There was no significant difference based on cell of origin in response to ICE SLT or to HDT. OS and EFS was similar for the GC and non-GC patients figure 1) ; in addition for those pts who received HDT/ASCT the OS for the GCB pts was 45% vs 54% for the non-GCB pts (p=0.9). We evaluated a number of markers important in untreated DLBCL to see if they had an impact in outcome in the second-line setting. As can be seen in table 3, none these markers had any significant impact on OS.
The current series is dominated by non-GCB patients as would be expected if patients with non-GCB DLBCL have poorer outcome as reported; though the distribution of GC and non-GCB patients is similar at diagnosis the higher proportion of non-GCB patients arises from inferior EFS and OS for non-GCB therefore the need for SLT 4 . There are two potential explanations for the failure of cell of origin to predict outcome for relapsed and refractory patients. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
